Skip to main content
TipRanks
Go Ultimate75% OFF

Edgewell Personal Care (EGZ) AI Stock Analysis

0 Followers
CH:EGZ

Edgewell Personal Care

(BX Swiss:EGZ)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Broad market-share gainsBroad share gains indicate that Edgewell’s brands remain competitive across categories and geographies, supporting retailer relevance and consumer demand. Sustained share retention can improve operating leverage and create a stronger base for future sales growth, particularly as distribution and brand investment continue.
Negative Factors
Revenue and profitability deteriorationThe decline in revenue and operating profitability shows that Edgewell’s current portfolio and cost structure are not yet converting brand activity into durable earnings. A net loss reduces internal funding capacity and increases execution pressure until growth, pricing, mix and expense discipline improve.

Edgewell Personal Care Business Overview & Revenue Model

Company Description

Edgewell Personal Care Company, along with its associated businesses, is a global producer and distributor of a diverse range of personal care items. The company organizes its operations into three main divisions: Wet Shave, Sun and Skin Care, and Fe...

Edgewell Personal Care Earnings Call Summary

Earnings Call Date:Nov 12, 2026(Q4-2026)|Next Earnings Date:Feb 09, 2027
Earnings Call SentimentPositive

The call was predominantly positive. Management highlighted a return to organic sales growth, stronger fourth-quarter margins and earnings, improved North American and international momentum, broad share gains, strong performance from Cremo and Hawaiian Tropic, and a broad fiscal 2027 innovation and transformation plan. These positives were tempered by Wet Shave supply constraints, the delayed manufacturing consolidation savings, fiscal-year operating profit and cash flow declines, inflation and tariff pressures, the loss of TSA income, restructuring charges and near-term first-quarter pressure.

Positive Updates

Strong Fourth-Quarter Financial Performance
Fourth-quarter organic net sales increased 3.1%, with growth in both North America and International. Gross margin expanded by more than 500 basis points, while adjusted EBITDA and adjusted earnings per share also grew meaningfully.

Negative Updates

Wet Shave Manufacturing Consolidation Delayed
Bringing new capacity online while Wet Shave growth accelerated was more challenging than anticipated. The consolidation timeline shifted by about six months, and associated savings are now expected to begin in fiscal 2028 rather than fiscal 2027.

Company Guidance

For fiscal '27, Edgewell expects organic net sales growth between 1% and 3%, with growth in both International and North America, International organic growth at mid-single-digit organic growth, and currency a 60 basis point headwind to reported net sales; Q1 organic net sales are expected to be flat to down approximately 1%. Adjusted gross margin is expected to expand approximately 60 basis points, adjusted SG&A to improve 90 basis points as a rate of sales, adjusted operating profit to grow by approximately 10%, and adjusted operating profit margin to increase approximately 70 basis points, while A&P is expected to rise about 80 basis points to approximately 13% of net sales, including approximately 14% of net sales in Q1. Adjusted EPS is expected to be $1.85 to $2.15 per share, growing approximately 3.5% at the midpoint, with approximately $0.20 of expected headwinds below operating profit, including $0.17 from the expiration of TSA income and $0.03 from a higher effective tax rate of approximately 24%, up about 1 point from fiscal '26; adjusted EBITDA is expected to be $250 million to $270 million, approximately 2% growth to prior year at the midpoint, absorbing approximately $11 million of TSA income, and adjusted free cash flow is expected to be $100 million to $120 million. The company expects 2/3 of adjusted EBITDA and approximately 80% of adjusted EPS in the second half, approximately 300 basis points of overall inflation, well over 250 basis points of productivity and volume absorption, and restructuring and related charges of approximately $55 million in fiscal '27.

Edgewell Personal Care Risk Analysis

Edgewell Personal Care disclosed 27 risk factors in its most recent earnings report. Edgewell Personal Care reported the most risks in the "Production" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Production - Risks related to the company’s ability to manufacture goods and services

Latest Risks Added

0 New Risks

Edgewell Personal Care Peers Comparison

Overall Rating

UnderperformOutperform
Sector (62)

Financial Indicators

CH:EGZ against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
CHDCHD78Outperform$25.89B33.6418.21%1.12%1.70%2.07%
PGPG72Outperform$389.04B24.8329.55%2.58%3.52%-3.74%
ULUL64Neutral$134.85B13.4458.26%3.40%-17.45%8.84%
Sector *62Neutral$20.33B14.63-3.31%3.23%1.93%-12.26%
HELEHELE55Neutral$820.78M-8.07-11.86%―0.52%84.94%

* Consumer Defensive Sector Average

Performance Comparison

0%50%100%CHDHELEPGULDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CH:EGZ and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CHDChurch & Dwight Company109.6827.9434.18%
HELEHelen Of Troy35.0916.7291.02%
PGProcter & Gamble Company167.8525.0117.51%
ULUnilever plc63.361.592.58%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.